• The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK is proposing new safety measures for pseudoephedrine medications because of rare reports of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS). • These conditions can cause inflammation and/or reduced blood supply to the brain, which are very rare side effects. • Pseudoephedrine is licensed for short-term relief of nasal congestion due to colds, flu, and allergies.

Side effects from medicines can be unexpected. You can help make medicines safer for everyone by reporting them. 💊 Search 'Yellow Card' 🔍 Medicines & Healthcare products Regulatory Agency #MHRAYellowCard #MedSafetyWeek | Berkshire Healthcare NHS Foundation Trust

Kaneez ep 19 | CE1

Meet Dr Melanie Ivarsson, from the global biotechnology company Moderna, to find out why she chose the UK for a billion-pound research and development program. https://www.newscientist.com/podcasts/transforming-clinical-trials-episode-3?utm_source=NSSocial&utm_medium=social&utm_campaign=NS_Social Sponsored by UK Business and Trade and Medicines & Healthcare Products Regulatory Agency | New Scientist